Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2015
At a glance
- Drugs Dasatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 31 Dec 2013 Protocol has been amended to add dasatinib 100mg, once per day.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.